Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to further develop a formulation and dose regimen of the
norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe
in an elderly population aged 60 years and above.